Owner ReVance Therapeutics, Inc.

Inventors Dake, Michael; Waugh, Jacob

Agent Spruson & Ferguson

Pub. Number AU-B-2009253761

Parent 2006209264

Filing date 24 December 2009

Wipo publication date 4 February 2010

Acceptance publication date 24 November 2011

C07K 7/00 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/28 (2006.01) Medicinal preparations containing peptides - Insulins

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 47/42 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Proteins

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61K 49/14 (2006.01) Preparations for testing

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/00 (2006.01) Peptides having more than 20 amino acids

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology